| Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases NE Aikawa, LVK Kupa, AC Medeiros-Ribeiro, CGS Saad, EFN Yuki, ... Annals of the rheumatic diseases 81 (7), 1036-1043, 2022 | 44 | 2022 |
| Ocular involvement in patients with spondyloarthritis ABS Bacchiega, GGM Balbi, MLG Ochtrop, FA de Andrade, RA Levy, ... Rheumatology 56 (12), 2060-2067, 2017 | 43 | 2017 |
| Neuro-ophthalmologic manifestations in systemic lupus erythematosus FA De Andrade, G Guimarães Moreira Balbi, LG Bortoloti de Azevedo, ... Lupus 26 (5), 522-528, 2017 | 42 | 2017 |
| The interplay between tuberculosis and systemic lupus erythematosus GGM Balbi, F Machado-Ribeiro, CDL Marques, F Signorelli, RA Levy Current Opinion in Rheumatology 30 (4), 395-402, 2018 | 39 | 2018 |
| Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic … AMM Franco, FMC Medina, GGM Balbi, RA Levy, F Signorelli Lupus, doi:10.1177/0961203320949667, 2020 | 19 | 2020 |
| Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome F Signorelli, GGM Balbi, NE Aikawa, CA Silva, LVK Kupa, ... Lupus 31 (8), 974-984, 2022 | 14 | 2022 |
| New and upcoming treatments in antiphospholipid syndrome: A comprehensive review F Signorelli, GGM Balbi, V Domingues, RA Levy Pharmacological Research 133, 108-120, 2018 | 11 | 2018 |
| Use of synthetic and biologic DMARDs during pregnancy GGM Balbi, V Domingues, GGM Balbi, GR De Jesús, RA Levy Expert Review of Clinical Immunology 15 (1), 27-39, 2019 | 8 | 2019 |
| Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS) GGM Balbi, MS Pacheco, OA Monticielo, A Funke, A Danowski, ... Advances in Rheumatology 60, 29, 2020 | 7 | 2020 |
| Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria? F Signorelli, GGM Balbi, E Bonfá, EF Borba, DCO Andrade Lupus 30 (11), 1732-1738, 2021 | 6 | 2021 |
| Non-criteria Antiphospholipid Antibodies: a Narrative Review A Funke, HL Staub, OA Monticielo, GGM Balbi, A Danowski, MB Santiago, ... Revista da Associação Médica Brasileira 66, 1595-1601, 2020 | 6 | 2020 |
| CoaguChek® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome MES Fonseca, GGM Balbi, F Signorelli, C Gouvea, D Andrade Lupus, 1-10, 2022 | 5 | 2022 |
| Rapidly progressive diffuse systemic sclerosis after local vitamins A, D and E complex injections: literature review and report of two cases GGM Balbi, RA Montes, VS Vilela, MAB Andrade, MM Nóbrega, ... Immunologic research 65, 285-292, 2017 | 5 | 2017 |
| Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry GGM Balbi, Y Ahmadzadeh, MG Tektonidou, V Pengo, S Sciascia, ... Rheumatology 63 (3), 772-779, 2024 | 3 | 2024 |
| Ocular retinal findings in asymptomatic patients with antiphospholipid syndrome secondary to systemic lupus erythematosus EDS Neto, TSR Neto, F Signorelli, GGM Balbi, AH Higashi, MLR Monteiro, ... Clinical Rheumatology 42 (8), 2105-2114, 2023 | 3 | 2023 |
| Ocular findings in asymptomatic patients with primary antiphospholipid syndrome TSR Neto, EDS Neto, GGM Balbi, F Signorelli, AH Higashi, MLR Monteiro, ... Lupus 31 (14), 1800-1807, 2022 | 3 | 2022 |
| Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal … GGM Balbi, Y Ahmadzadeh, MG Tektonidou, V Pengo, S Sciascia, ... Arthritis & Rheumatology 73 (Suppl 10), 71, 2021 | 3 | 2021 |
| Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised … JBH Adelhelm, R Christensen, GGM Balbi, A Voss Lupus science & medicine 10 (2), e001018, 2023 | 2 | 2023 |
| Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of … G Balbi, G de Jesus, FV Signorelli ARTHRITIS & RHEUMATOLOGY 74, 1362-1364, 2022 | 2 | 2022 |
| Anorectal diseases in patients with antiphospholipid syndrome: a cross-sectional study E Cunha, V Guzela, GGM Balbi, C Sobrado, D Andrade Advances in Rheumatology 60, 51, 2020 | 2 | 2020 |
Roger A LevyGSK在 gsk.com 的电子邮件经过验证
